Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome
Status:
Completed
Trial end date:
2018-06-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of two doses of LP08
compared to placebo. Hypothesis: Safety of the LP-08 therapy will not be significantly
different from the placebo group. Secondary Efficacy Endpoints: A matched-pair data analysis
design will be employed, i.e. the measured outcomes will be subjects' improvements in
quantitative and qualitative measures of the disease condition being assessed prior to and
after LP-08 instillations at four and eight weeks follow-up visits